MissionIR Articles
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Issues Update on Nasdaq Compliance Status
Nemaura (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with continued listed…
-
Nemaura Medical, Inc. (NASDAQ: NMRD) Featured in Coverage of The MicroCap Rodeo’s 3rd Annual Winter Wonderful and Best Ideas Investor Conference
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Collaborates with EVERSANA(R) to Bring BEATdiabetes Solution to Market
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a preliminary agreement with EVERSANA(R), a pioneer…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate in H.C. Wainwright Global Hybrid Investment Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, and its CEO Dr. Faz Chowdhury will be attending the upcoming H.C. Wainwright…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Planet MicroCap Showcase 2022
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that it will be presenting at the Planet MicroCap Showcase…
-
MissionIRNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct
Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming Maxim Group 2022 Virtual Growth Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be attending and participating at this month’s Maxim…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Valuable AI-Powered Insights to Diabetes Market
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Commercialization Phase of Its Corporate Development, Recognizes First-Ever Revenues
Nemaura Medical (NASDAQ: NMRD) recently announced its Q3 FY 2022 results for the three months ended Dec. 31, 2021. The company reported revenues of $183,628 due to the initial shipments made over the past quarter…
-
Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program
Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke Companies in diagnostic space posting record revenues, double-digit YOY increases Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology,…
-
MissionIRNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success
Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Recognized as Innovator of the Year, Awarded Top Honors for Innovation in MedTech, Life Sciences
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its receipt of the top award as Innovator of the…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Publishes 3QFY2022 Results; Company Reports its Inaugural Quarterly Revenues
Nemaura Medical has recently reported its 3QFY2022 (4QCY2021) results, with the company recognizing its inaugural revenues of $183,628 over the quarter The company also announced that it held $23 million in cash reserves as of…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Producing What Was Thought to Be Implausible
Nemaura Medical (NASDAQ: NMRD) has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Seeks to Provide Non-Invasive Glucose Monitoring Solutions to Millions of Patients Worldwide
Over 420 million people around the globe currently have diabetes, with the figure set to rise by 55% over the next 25 years Millions of patients required to measure their blood glucose levels daily to…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Reports Financial Results, Business Updates for Q3 2022
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has released its Q3 financial results and business updates. The company noted that,…
-
Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference
NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD’s sugarBEAT(R) devices measure glucose at the…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth
Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate
The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have…
Search Articles
Latest Articles
- MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures First Texas Electronic Monitoring Contract
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Advances Kingston Facility as Samarium Risk Escalates
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) Making Progress on El Domo Construction as Production Growth Continues in China
- Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology